BioSpace News Archive

Pictured: Astellas' Americas headquarters in Illin

Policy

Astellas Withdraws IRA Lawsuit After Xtandi Avoids Drug Price Negotiations

The company has withdrawn a suit against the Department of Health and Human Services after its prostate cancer therapy was not included in Medicare’s initial drug price negotiation list.

September 7, 2023

·

2 min read

·

Tristan Manalac

Pictured: Roche tower in Basel, Switzerland

Drug Development

Roche Sees Return on $310M Investment with Alnylam’s Phase II Hypertension Win

The RNAi therapy, which the companies are co-developing and commercializing, reduced blood pressure in hypertensive patients with high cardiovascular risk by 15 mmHg over placebo.

September 7, 2023

·

2 min read

·

Kate Goodwin

Scientific data analysis concept_iStock, gorodenko

Drug Development

Opinion: Reexamination of Failed DMD Trial a Much-Needed Reckoning for FibroGen

A thorough reassessment of the confounders between FibroGen’s trials is necessary to salvage the company’s Duchenne Muscular Dystrophy program and regain investor confidence.

September 7, 2023

·

2 min read

·

Jia Jie Chen

Pictured: Bristol Myers Squibb office in California

Policy

BMS Accused by HMO of Patent Fraud to Allegedly Sustain Pomalyst Monopoly

Blue Cross and Blue Shield of Louisiana has filed a case against Bristol Myers Squibb alleging the company conducted patent fraud to extend protections for its multiple myeloma drug Pomalyst.

September 7, 2023

·

2 min read

·

Tristan Manalac

Drug Development

FDA Action Alert: GSK and Alnylam

After a three-month delay, GSK expects an FDA verdict for its myelofibrosis candidate, while Alnylam gears up for an advisory committee meeting discussing patisiran in cardiomyopathy of ATTR amyloidosis.

September 7, 2023

·

3 min read

·

Tristan Manalac

Pictured: Illustration of a human body with the liver highlighted

Drug Development

CymaBay’s Liver Disease Candidate Hits Phase III Primary, Secondary Endpoints

Analysts said CymaBay’s seladelpar is emerging as the “therapy of choice in the second-line setting” and “could impact the treatment landscape” across a spectrum of primary biliary cholangitis patients.

September 7, 2023

·

2 min read

·

Connor Lynch

Drug Development

J&J Terminates Phase III Study of Cardio Asset in Pulmonary Hypertension

At the recommendation of an independent data monitoring committee, J&J decided to stop the MACiTEPH trial in chronic thromboembolic pulmonary hypertension due to futility.

September 7, 2023

·

2 min read

·

Tristan Manalac

Drug Development

Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA

Medivir AB announces that data on the company’s leading program fostroxacitabine bralpamide and its potential effect on hepatocellular carcinoma, will be presented at the International Liver Cancer Association Annual Meeting, September 7-9 in Amsterdam.

September 7, 2023

·

4 min read

Ohh-Med Medical Launches Ohh-Med UK to expand the worldwide reach of Vertica, the company’s home-use device for treating erectile dysfunction

Ohh-Med Medical, a medtech startup located in the Tiberias Industrial Zone, has recently launched Ohh-Med UK, a wholly owned subsidiary located in England, to sell, market, and support sales of the Vertica medical device throughout the United Kingdom.

September 7, 2023

·

2 min read

Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Opthea Limited announced that Mr. Tim Morris, the Company’s Chief Financial Officer will present at H.C. Wainwright’s 25th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 11th – 13th, 2023.

September 7, 2023

·

2 min read